Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-16-119063
Filing Date
2016-08-15
Accepted
2016-08-15 10:01:38
Documents
44
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v446270_10q.htm 10-Q 236103
2 EXHIBIT 31.1 v446270_ex31-1.htm EX-31.1 8086
3 EXHIBIT 31.2 v446270_ex31-2.htm EX-31.2 7974
4 EXHIBIT 32.1 v446270_ex32-1.htm EX-32.1 4580
5 EXHIBIT 32.2 v446270_ex32-2.htm EX-32.2 4483
  Complete submission text file 0001144204-16-119063.txt   2130425

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT casi-20160630.xml EX-101.INS 322240
7 XBRL TAXONOMY EXTENSION SCHEMA casi-20160630.xsd EX-101.SCH 27011
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE casi-20160630_cal.xml EX-101.CAL 21247
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE casi-20160630_def.xml EX-101.DEF 173016
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20160630_lab.xml EX-101.LAB 206261
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20160630_pre.xml EX-101.PRE 194613
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 161830528
SIC: 2836 Biological Products, (No Diagnostic Substances)